DUBLIN--(BUSINESS WIRE)--Aug 21, 2018--The "The Corporate Reputation of Pharma Companies, 2017 - The Patient Perspective of 74 HIV/Aids Patient Groups - HIV/Aids Edition" report has been added to ResearchAndMarkets.com's offering.

Still discontented with pharma...

The views of 74 HIV/AIDS patient groups. Drawn from a November 2017-February 2018 survey.

HIV/AIDS patient groups have been among the most forthright and active elements of the patient movement since the days of the founding of the very first of them. Yet, despite the significant improvements in HIV/AIDS treatments made over the decades, feelings of discontent among HIV/AIDS patient groups still exist.

The 2017 Corporate-Reputation survey found HIV/AIDS patient groups to be especially critical of the progress that the pharmaceutical industry may (or may not) have made on a whole set of issues, including:

Integrity Transparency in the sharing of clinical-trials data Patient safety

Underlying these negative sentiments was a real feeling among HIV/AIDS patient groups that people living with HIV/AIDS were increasingly desperate for new products capable of providing a tangible difference to their lives, delivering:

Higher potencies in drugs Reduced side effects Once-daily dosages; and Less drug resistance.

On the topic of the industry's ability to innovate in the area of HIV/AIDS, only 46% of the HIV/AIDS patient groups thought pharma to be Excellent or Good in 2017. To put such a finding in context, 74% of patient groups specialising in haemophilia saw the pharma industry as Excellent or Good at innovating in the subject area of haemophilia in 2017.

In fact, as few as 31% of 2017's respondent HIV/AIDS patient groups thought that the pharmaceutical industry had an Excellent or Good corporate reputation that year, a figure well below the 44% reported by HIV/AIDS patient groups in the 2016 survey, and also below the equivalent figure from patient groups therapy wide (43%) in 2017.

... but HIV/AIDS patient groups want better R&D and think that greater engagement is key to achieving this goal

Two main themes arising out of HIV/AIDS patient-group comments to the 2017 Corporate-Reputation survey is the wish for pharmaceutical companies to:

actively engage themselves in the communities affected by HIV/AIDS; and create better channels of communication with HIV/AIDS patient groups.

Comments of this nature were made by HIV/AIDS patient groups from all parts of the world. One compelling reason for such engagement was that HIV/AIDS patient groups felt themselves well equipped to guide pharma's R&D activities toward products that people living with HIV/AIDS truly need.

So, how did the companies perform at corporate reputation in 2017, in the viewpoints of HIV/AIDS patient groups?

Ranking at corporate reputation is measured by patient groups familiar with a company.

ViiV Healthcare ranked overall 1st in 2017 for corporate reputation among HIV/AIDS patient groups familiar with the company. ViiV has now held this rank for five years in a row. ViiV was also 1st in 2017 for eight of the 12 individual indicators of corporate reputation. Gilead came next, ranking overall 2nd. The company was ranked 1st for four of the 12 indicators of corporate reputation. Janssen was ranked overall 3rd. Janssen also had the highest Net Promoter Score (NPS) in the HIV/AIDS element of the 2017 Corporate-Reputation survey: +33.3%. AbbVie ranked overall 4th. And... GSK, which acts on behalf of ViiV in some geographic markets, came 5th.

Key Topics Covered:

Executive Summary HIV/Aids Patient-Group Relationships With Pharma, 2017 Industry-Wide Findings From HIV/Aids Patient Groups, 2017 Rankings Of The 10 Pharma Companies, 2017 V. 2016 Among HIV/Aids Patient Groups Familiar With The Companies Positionings Of Seven Pharma Companies, 2017 V. 2016 Among HIV/Aids Patient Groups That Work/Partner With The Companies Profiles Of The 10 Companies, 2017  Abbvie Boehringer Ingelheim Bristol-Myers Squibb Gilead GSK Janssen Merck & Co/MSD Roche Sanofi ViiV Healthcare

For more information about this report visit https://www.researchandmarkets.com/research/hfztjs/_hivaids_patient?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180821005326/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Pharmaceuticals



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/21/2018 06:38 AM/DISC: 08/21/2018 06:38 AM